Department of Neurosurgery, Georgetown University Hospital, Research Center for Genetic Medicine, Children's National Medical Center NW, Washington, DC 20010, USA.
Neuro Oncol. 2012 May;14(5):547-60. doi: 10.1093/neuonc/nos067. Epub 2012 Apr 5.
Diffuse intrinsic pontine glioma (DIPG) is a leading cause of brain tumor-related death in children. DIPG is not surgically resectable, resulting in a paucity of tissue available for molecular studies. As such, tumor biology is poorly understood, and, currently, there are no effective treatments. In the absence of frozen tumor specimens, body fluids--such as cerebrospinal fluid (CSF), serum, and urine--can serve as more readily accessible vehicles for detecting tumor-secreted proteins. We analyzed a total of 76 specimens, including CSF, serum, urine, and normal and tumor brainstem tissue. Protein profiling of CSF from patients with DIPG was generated by mass spectrometry using an LTQ-Orbitrap-XL and database search using the Sequest algorithm. Quantitative and statistical analyses were performed with ProteoIQ and Partek Genomics Suite. A total of 528 unique proteins were identified, 71% of which are known secreted proteins. CSF proteomic analysis revealed selective upregulation of Cyclophillin A (CypA) and dimethylarginase 1 (DDAH1) in DIPG (n = 10), compared with controls (n = 4). Protein expression was further validated with Western blot analysis and immunohistochemical assays using CSF, brain tissue, serum, and urine from DIPG and control specimens. Immunohistochemical staining showed selective upregulation of secreted but not cytosolic CypA and DDAH1 in patients with DIPG. In this study, we present the first comprehensive protein profile of CSF specimens from patients with DIPG to demonstrate selective expression of tumor proteins potentially involved in brainstem gliomagenesis. Detection of secreted CypA and DDAH1 in serum and urine has potential clinical application, with implications for assessing treatment response and detecting tumor recurrence in patients with DIPG.
弥漫内生型桥脑胶质瘤(DIPG)是儿童脑瘤相关死亡的主要原因。DIPG 无法通过手术切除,因此可供分子研究的组织非常有限。因此,肿瘤生物学尚未得到充分了解,目前也没有有效的治疗方法。由于缺乏冷冻的肿瘤标本,体液(如脑脊液、血清和尿液)可以作为更易获得的检测肿瘤分泌蛋白的载体。我们分析了总共 76 个标本,包括脑脊液、血清、尿液以及正常和肿瘤脑干组织。使用 LTQ-Orbitrap-XL 通过质谱法对 DIPG 患者的脑脊液进行蛋白质谱分析,并使用 Sequest 算法对数据库进行搜索。使用 ProteoIQ 和 Partek Genomics Suite 进行定量和统计分析。总共鉴定出 528 个独特的蛋白质,其中 71%是已知的分泌蛋白。与对照组(n=4)相比,DIPG(n=10)患者的脑脊液蛋白质组分析显示环孢素 A(CypA)和二甲基精氨酸酶 1(DDAH1)选择性上调。使用来自 DIPG 和对照组标本的脑脊液、脑组织、血清和尿液进行 Western blot 分析和免疫组织化学检测进一步验证了蛋白质表达。免疫组织化学染色显示,DIPG 患者中分泌型但非胞浆型 CypA 和 DDAH1 选择性上调。在这项研究中,我们首次展示了来自 DIPG 患者的脑脊液标本的全面蛋白质谱,证明了潜在参与脑干神经胶质瘤发生的肿瘤蛋白的选择性表达。在血清和尿液中检测到分泌型 CypA 和 DDAH1 具有潜在的临床应用价值,可用于评估治疗反应和检测 DIPG 患者的肿瘤复发。